4th Quarter - Report

CVS HEALTH (AND SUBSIDIARIES) for CVS HEALTH (AND SUBSIDIARIES)

Firm
Client
Income
—
Expenses
$1,680,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Veterans VET

Issues related to veterans access to healthcare and VA CHOICE Act reauthorization. S. 1526, The Veterans Access to Community Care Act of 2017 H.R. 4242, The VA Care in the Community Act S. 2184, The Veterans Community Care and Access Act

LobbyistCovered position, as disclosed
SHANNON PENBERTHY —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Veterans Affairs, Dept of (VA); SENATE; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS)

Bills named: S. 1526 (115th), S. 2184 (115th), H.R. 4242 (115th)

Health Issues HCR

Issues related to implementation and changes to the Affordable Care Act.

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
ASHLI PALMER —
SHANNON PENBERTHY —

Contacted: Veterans Affairs, Dept of (VA); Office of Management & Budget (OMB); SENATE; White House Office; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Labor Issues/Antitrust/Workplace LBR

Issues related to CVS Health announced merger with Aetna.

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
TEGAN GELFAND —
ASHLI PALMER —
SHANNON PENBERTHY —
MELISSA SCHULMAN —

Contacted: Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE; Health & Human Services, Dept of (HHS); White House Office

Taxation/Internal Revenue Code TAX

Issues related to corporate tax reform, health savings accounts, and taxes included in the Affordable Care Act. H.R.1, The Tax Cuts and Jobs Act H.R. 4620, The Protecting Families and Small Businesses Act of 2017

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
TEGAN GELFAND —
SHANNON PENBERTHY —
MELISSA SCHULMAN —

Contacted: HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Office of Management & Budget (OMB); SENATE; Health & Human Services, Dept of (HHS); White House Office

Bills named: H.R. 4620 (115th), H.R. 1 (115th)

Copyright/Patent/Trademark CPT

Issues related to barriers to generic drug and biosimilar market entry including pay-for-delay and REMS. S. 124, The Preserve Access to Affordable Generics Act of 2017 S.771/H.R. 1776, The Improving Access to Affordable Prescription Drugs Act of 2017 H.R. 2051, The Fair Access for Safe and Timely Generics Act of 2017 S. 974/H.R. 2212, The Creating and Restoring Equal Access to Equivalent Samples Act of 2017

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
ASHLI PALMER —
SHANNON PENBERTHY —
MELISSA SCHULMAN —

Contacted: White House Office; Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; SENATE; Office of Management & Budget (OMB)

Bills named: S. 974 (115th), S. 771 (115th), S. 124 (115th), H.R. 2212 (115th), H.R. 2051 (115th), H.R. 1776 (115th)

Medicare/Medicaid MMM

Issues related to Medicare Part D and Medicare payment for home infusion. S.413/H.R. 1039, The Improving Transparency and Accuracy in Medicare Part D Drug Spending Act of 2017 H.R.1316, The Prescription Drug Price Transparency Act of 2017 S.771/H.R. 1776, The Improving Access to Affordable Prescription Drugs Act of 2017 H.R. 3528, The Every Prescription Conveyed Safely Act of 2017 S. 1738/H.R. 3163, The Medicare Home Infusion Therapy Act of 2017 H.R. 3178, The Medicare Part B Improvement Act of 2017

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
ASHLI PALMER —
SHANNON PENBERTHY —
MELISSA SCHULMAN —

Contacted: Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); White House Office; SENATE

Bills named: H.R. 1316 (115th), H.R. 3528 (115th), S. 413 (115th), H.R. 1039 (115th), H.R. 3163 (115th), H.R. 1776 (115th), H.R. 3178 (115th), S. 771 (115th), S. 1738 (115th)

Pharmacy PHA

Issues related to medication adherence, generic drug approvals, biologic exclusivity periods, and drug price transparency. H.R.1316, The Prescription Drug Price Transparency Act of 2017 S.771/H.R. 1776, The Improving Access To Affordable Prescription Drugs Act of 2017 S. 778/H.R. 1854, The Prescription Drug Monitoring Act of 2017 H.R. 3528, The Every Prescription Conveyed Safely Act of 2017 S.892, The Opioid Addiction Prevention Act of 2017

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
ASHLI PALMER —
SHANNON PENBERTHY —
MELISSA SCHULMAN —

Contacted: SENATE; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); White House Office; Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1316 (115th), S. 892 (115th), S. 778 (115th), H.R. 1776 (115th), S. 771 (115th), H.R. 1854 (115th), H.R. 3528 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.